Date:	1 st August 2022
Your Name:	Akihiro Nagoya
Manuscript Title:	CKAP4 is a potential exosomal biomarker and therapeutic target for lung cancer
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _X_ None	planning of the work
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: past X None X None	36 months
4	Consulting fees	_X_ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X_ None	
6	Payment for expert testimony	_X_ None	
7	Support for attending meetings and/or travel	_X_ None	
8	Patents planned, issued or pending	<u>X</u>	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_ None	
11	Stock or stock options	_X_ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_ None	
13	Other financial or non- financial interests	X None	
	ease summarize the above conflicts of interest to		lowing box:

Da	te:1	.st August 2022	
Yo	ur Name:R	yota Sada	
Ma Ma	anuscript Title:CKAP4 is a anuscript number (if known)	a potential exosomal biom	arker and therapeutic target for lung cancer
rel par to rel The ma The to me	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only. e author's relationships/act the epidemiology of hypertedication, even if that medication.	manuscript. "Related" means affected by the content of the author's relationship in the content of the content	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	✓ _None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	/ None	
3	Royalties or licenses	None	
4	Consulting fees	_√None	

5	Payment or nonoraria for	_ ✓ None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	✓ None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	✓ None	
	pending		
9	Safety Monitoring Board or	_ / None	
	Advisory Board		
10	Leadership or fiduciary role	/ None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	✓ None	
11	Stock of Stock options	_vNone	
12	Receipt of equipment,	✓ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_ √ None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	I have completed the ICMIF un	iform disclosure form. I have	no conflicts of interest to declare.
_			

Date:	1 st August 2022
Your Name:	Hirokazu Kimura
Manuscript Ti	tle: CKAP4 is a potential exosomal biomarker and therapeutic target for lung cancer
Manuscript n	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All		planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_ None	
3	Royalties or licenses	_X_ None	
4	Consulting fees	_X_ None	

5	Payment or honoraria for	_X_ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
C	educational events	V Name	
6	Payment for expert testimony	_X_ None	
	testimony		
7	Support for attending	_X_ None	
,	meetings and/or travel	_X_None	
	,		
8	Patents planned, issued or	_X_	
	pending		
9	Participation on a Data	_X_ None	
	Safety Monitoring Board or Advisory Board		
10		V N	
10	Leadership or fiduciary role in other board, society,	_X_ None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_ None	
12	Receipt of equipment,	_X_ None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_X_ None	
10	financial interests	_X_None	
Ple	ease summarize the above o	onflict of interest in the	e following box:
	I declare that I have no conflict	of interest.	

Date:	1 st August 2022
Your Name:	Hideki Yamamoto
Manuscript Title:	CKAP4 is a potential exosomal biomarker and therapeutic target for lung cancer
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_ None	
3	Royalties or licenses	_X_ None	
4	Consulting fees	_X_ None	

etures, presentations, eakers bureaus, enuscript writing or ucational events yment for expert stimony pport for attending eetings and/or travel tents planned, issued or nding rticipation on a Data fety Monitoring Board or	XNone			
pricipation on a Data	_X_ None			
pport for attending eetings and/or travel tents planned, issued or nding rticipation on a Data	_X_ None			
pport for attending eetings and/or travel tents planned, issued or nding	_X_ None			
pport for attending eetings and/or travel tents planned, issued or nding	_X_			
tents planned, issued or nding	_X_			
tents planned, issued or nding	_X_			
nding rticipation on a Data				
nding rticipation on a Data				
nding rticipation on a Data				
rticipation on a Data	_ <u>X_</u> None			
	X None			
	X None			
icty Monitoring board of				
lvisory Board				
adership or fiduciary role	_X_ None			
other board, society,				
mmittee or advocacy				
oup, paid or unpaid				
ock or stock options	_X_ None			
ceipt of equipment,	_X_ None			
aterials, drugs, medical	_X_None			
iting, gifts or other rvices				
her financial or non-	X_ None			
ancial interests				
e summarize the above co	onflict of interest in the f	following box:		
r	vices ner financial or non- ancial interests	vices ner financial or non- ancial interests X_ None	vices ner financial or non- X None	vices ner financial or non- ancial interests X_ None

Da	ate:	1 August 2	:022
	our Name:	1) MOS	
	• ——		biomarker and therapeutic target for lung cancer
M	anuscript number (if known):	
re pa to	lated to the content of your arties whose interests may b	manuscript. "Related" mo e affected by the content necessarily indicate a bias	Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.
	ne following questions apply anuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>
to m	the epidemiology of hypert edication, even if that medic	ension, you should declar cation is not mentioned in pport for the work report	e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive n the manuscript. red in this manuscript without time limit. For all other item
	T	Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initi	al planning of the work
L	All support for the present	_X_ None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.	1	
_		Time frame: pas	st 36 months
2	Grants or contracts from	Time frame: pas	st 36 months
<u>}</u>	any entity (if not indicated		st 36 months
?	any entity (if not indicated in item #1 above).	_X_ None	st 36 months
?	any entity (if not indicated		st 36 months
2	any entity (if not indicated in item #1 above).	_X_ None	st 36 months
2	any entity (if not indicated in item #1 above). Royalties or licenses	_X_None	st 36 months
<u>?</u>	any entity (if not indicated in item #1 above).	_X_ None	st 36 months
3	any entity (if not indicated in item #1 above). Royalties or licenses	_X_None	st 36 months
3	any entity (if not indicated in item #1 above). Royalties or licenses	_X_None	st 36 months

speakers bureaus, manuscript writing or

	educational events		
6	Payment for expert	X None	
_	testimony		
	•		
7	Support for attending meetings and/or travel	_X_ None	
	meetings and/or traver		
8	Patents planned, issued or	_X_	
	pending		
9	Participation on a Data	_X_ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_ None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_X_ None	
	Stock of Stock options	_X_None	
12	Receipt of equipment,	_X_ None	
	materials, drugs, medical		
İ	writing, gifts or other		
	services		
13	Other financial or non-	_X_ None	
	financial interests		
Ple	ease summarize the above o	conflict of interest in the fo	llowing box:
Γ			
1			
			1
_			

Your Name:	of miges (
Manuscript Title: CKA	AP4 is a potential exosomal biomarker and therapeutic target for lung cancer
Manuscript number (if know	wn):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_X_ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_X_ None	
4	Consulting fees	_X_ None	
5	Payment or honoraria for	_X_ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		

	educational events		
6	Payment for expert	_X_ None	
	testimony		
7	Support for attending meetings and/or travel	_X_ None	
	,		
8	Patents planned, issued or	<u>x</u>	
	pending		
9	Participation on a Data	_X_ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_ None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid		
11	Stock or stock options	_X_ None	
12	Receipt of equipment,	V Nana	
12	materials, drugs, medical	_X_ None	
	writing, gifts or other		
	services		
13	Other financial or non-	_X_ None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
_			
L			

Date:		L st August 2022
Your Name:	Eiichi Morii	
Manuscript Title:	CKAP4 is a potential	exosomal biomarker and therapeutic target for lung cancer
Manuscript number	(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_ None	
2	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: past _X_ None _X_ None	36 months
4	Consulting fees	_X_ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X_ None	
6	Payment for expert testimony	_X_ None	
7	Support for attending meetings and/or travel	_ <u>X_</u> None	
8	Patents planned, issued or pending	<u>X</u>	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_ None	
11	Stock or stock options	_X_ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ <u>X_</u> None	
13	Other financial or non- financial interests	_X_ None	
Ple	ease summarize the above c	onflict of interest in the	e following box:

Date:	1 st August 2022
Your Name:	Yasushi Shintani
Manuscript Title:	CKAP4 is a potential exosomal biomarker and therapeutic target for lung cancer
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial X None	planning of the work
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: past X None X None	36 months
4	Consulting fees	_X_ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	_X_ None
6	Payment for expert testimony	_X_ None
7	Support for attending meetings and/or travel	_X_None
8	Patents planned, issued or pending	<u>X</u>
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_ None
11	Stock or stock options	_X_ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_ None
13	Other financial or non- financial interests	_X_ None
Ple	ease summarize the above c	onflict of interest in the following box:

Date:	1 st August 2022	
Your Name:	Akira Kikuchi	
Manuscript Title:	CKAP4 is a potential exosomal biomarker and therapeutic target for lung cancer	
Manuscript number	(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_ None	
2	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: past _X_ None _X_ None	36 months
4	Consulting fees	_X_ None	

_	Daywa and and a		
5	Payment or honoraria for	_X_ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	•		
7	Support for attending	_X_ None	
′	meetings and/or travel	_X_None	
	meetings and/or traver		
8	Patents planned, issued or pending	X None	
	F 0		
0	Dorticipation on a Data	V Ners	
9	Participation on a Data	_X_ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	President of Federation	unpaid
	in other board, society,	of Asia and Oceanian	
	committee or advocacy	Biochemist and	
	group, paid or unpaid		
	g. cup, para cr ampara	Molecular Biologist	
		(FAOBMB)	
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	_X_ None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	_X_ None	
	financial interests		
		•	

Please summarize the above conflict of interest in the following box:

Akira Kikuchi reported to serve as the President of Federation of Asia and Oceanian Biochemis Molecular Biologist (FAOBMB) without pay.		

Please place an "X" next to the following statement to indicate your agreement:			
X I certify that I have answered every question and have not altered the wording of any of the questions on this form.			